The post As per a peer-reviewed Lancet study, the efficacy of covaxin is 77.8% appeared first on The Edge Media.
]]>
According to the Lancet study, the vaccination produces a strong antibody response. There were no serious vaccine-related adverse events or deaths among the trial participants. The bulk of the side effects, such as headaches, weariness, fever, and injection site soreness, were minor and occurred within seven days following immunization.
The post As per a peer-reviewed Lancet study, the efficacy of covaxin is 77.8% appeared first on The Edge Media.
]]>The post According to a WHO official, Bharat Biotech’s Covid vaccine could be approved “within the next 24 hours” appeared first on The Edge Media.
]]>
“If all is in place and all goes well and if the committee is satisfied, we would expect a recommendation within the next 24 hours or so,” Margaret Harris told journalists at a UN press briefing.
On April 19, Bharat Biotech, based in Hyderabad, submitted an EOI (Expression of Interest) to the WHO for the vaccine’s Emergency Use Listing (EUL).
The post According to a WHO official, Bharat Biotech’s Covid vaccine could be approved “within the next 24 hours” appeared first on The Edge Media.
]]>The post In authorizing India’s Covaxin injection, the WHO said it “cannot take corners” appeared first on The Edge Media.
]]>
Bharat Biotech, which collaborated with an Indian governmental research entity to produce Covaxin, began sharing data with the WHO in early July. Even before the end of a late-stage trial, which found the vaccination to be 78 percent effective, the vaccine was given emergency use authorization in India in January.
The post In authorizing India’s Covaxin injection, the WHO said it “cannot take corners” appeared first on The Edge Media.
]]>The post Bharat Biotech Put A Stop To Brazilian Agreement Of Vaccine Supply appeared first on The Edge Media.
]]>Precisa Medicamentos is Bharat Biotech’s Brazilian partner, assisting, guiding, and supporting the company with regulatory filings, licensing, sales, coverage, and the performance of phase III clinical studies, among other things.
According to the company, Bharat Biotech is pursuing licences in numerous nations based on the legal criteria of each country.
The post Bharat Biotech Put A Stop To Brazilian Agreement Of Vaccine Supply appeared first on The Edge Media.
]]>The post Bharat Biotech To Supply 500M Covaxin Doses To Center appeared first on The Edge Media.
]]>Bharati Pravin Pawar, Minister of State for Health, stated in Parliament on Tuesday that the Serum Institute of India furnished the Centre with 5.45 crore (54.5 million) doses of Covaxin by Bharat Biotech and 36.01 crores (360 million) doses of Covishield from January to July 16.
The post Bharat Biotech To Supply 500M Covaxin Doses To Center appeared first on The Edge Media.
]]>The post Bharat Biotech Going To Have A Meeting With WHO Next Wednesday appeared first on The Edge Media.
]]>The pharma business has faced challenges in obtaining Covaxin authorized in some foreign nations because it lacks Phase-3 trial results, which is required for a WHO approval to ship the vaccine and include it in the much-coveted coronavirus “vaccine passport.”
Bharat Biotech previously informed ANI that Covaxin’s Phase-3 trial data would be made public in July, after which the firm would seek a full license of the Covid-19 vaccine in India.
The post Bharat Biotech Going To Have A Meeting With WHO Next Wednesday appeared first on The Edge Media.
]]>The post New plant in Gujrat to ramp up Covaxin production by 200 million appeared first on The Edge Media.
]]>Earlier, Bharat Biotech had deployed multiple production lines at its Hyderabad and Bengaluru campuses to meet the country’s growing need of vaccine. There was a drastic drop in the speed of the national vaccine drive due to depleted stocks of vaccine.
The company ramped up capacities at its own established campuses that are specialized in manufacturing inactivated viral vaccines under the highest levels of biosafety.
The post New plant in Gujrat to ramp up Covaxin production by 200 million appeared first on The Edge Media.
]]>The post Nitin Gadkari says that more pharma companies should be allowed to make vaccine appeared first on The Edge Media.
]]>Mr. Gadkari said while addressing virtually to the Vice Chancellors of Universities that he will also request Prime Minister Narendra Modi to bring a law that would allow more pharma companies to manufacture the life-saving vaccine.
He said,”If the demand of vaccine is more than its supply then it creates a problem. So, instead of one company, 10 more companies should be allowed to make vaccines by paying 10 per cent royalty to the original patent holder of the vaccine”.
At the recent time, there are only two companies that are producing the vaccine- Bharat Biotech and Serum Institute of India namely Covaxin and Covishield respectively.
The post Nitin Gadkari says that more pharma companies should be allowed to make vaccine appeared first on The Edge Media.
]]>The post Phase 2/3 trials of Covaxin in children to begin in 10-12 days appeared first on The Edge Media.
]]>Dr. VK Paul, a member of the health NITI Aayog said,”COVAXIN has been approved by the Drugs Controller General of India (DCGI), for phase II/III clinical trials in the age group of 2 to 18 years. I have been told that trials will begin in the next 10-12 days”. The trial will be done in 525 subjects at various sites.
Covaxin, together with Covishield, is being used to vaccinate adults in the country. The US authorized Pfizer and BioNTech’s vaccine for children ageing from 2 to 15 years last week.
The post Phase 2/3 trials of Covaxin in children to begin in 10-12 days appeared first on The Edge Media.
]]>The post Results of first stage of Bharat Biotech covid-19 vaccine successful, no side effects shown appeared first on The Edge Media.
]]>The post Results of first stage of Bharat Biotech covid-19 vaccine successful, no side effects shown appeared first on The Edge Media.
]]>